Pfizer (NYSE:PFE) said today that its Hospira subsidiary and healthcare IT group Iatric Systems inked a partnership deal to develop interoperability between Hospira’s smart infusion pumps and Iatric’s Accelero Connect integration software.

The 2 companies said they are currently piloting smart-pump EMR interoperability at an undisclosed US hospital.

“Hospira is proud to partner with Iatric Systems to make IV-EMR interoperability available to the hundreds of hospitals where Iatric Systems performs integration. After already becoming the first smart pump vendor to successfully integrate with three major EMR platforms, we are excited to add another major EMR system to the list once this pilot site goes live,” Hospira prez Julie Sawyer-Montgomery said in a press release

The project aims to provide 2-way communication between the system to enable pump programming automation with validated EMR medication orders, as well as documenting medication administrations into the patient’s EMR.

“Smart pump-EMR integration can help save lives and money. Simply put, it’s the right thing to do. On the clinical side, we’re sending IV medication orders from the EMR to the infusion pump, which significantly minimizes the chance of human errors and helps improve patient outcomes. On the financial side, we’re sending start times, stop times, and other infusion details from the pump back to the EMR, which saves nurses time and may improve hospital reimbursements. This is a win-win for everyone, and we’re proud to partner with Hospira in this advancement of patient care,” Iatric Systems pzrez Frank Fortner said in prepared remarks.

In October, ICU Medical (NSDQ:ICUI) said it agreed to pay $1 billion in cash and stock for the Hospira infusion pump business, confirming rumors that swirled earlier this year that the drug giant was looking to sell the business.

The deal calls for ICU Medical to put up $400 million worth of new shares and $600 million in cash, leaving Pfizer with a 16.6% stake in ICU. The acquisition, expected to close during the 1st quarter of 2017, includes IV pumps, solutions and devices made by the Hospira Infusion Systems business. ICU pegged its pro-forma annual revenues after the deal at roughly $1.45 billion, based on trailing 12-month results as of June.